FIGURE 6.
IFNγ enhances anti-CD38 therapy in vivo. A, AML cell lines MOLM-13, MV4-11, OCI-AML3, and THP-1 (n ≥ 3 separate experiments each) were treated for 24 h with or without 10 ng/ml IFNγ and then incubated for 3 h with or without 10 μg/ml anti-CD38 antibody (CD38). IFNγ was added to the respective treatments for 18 h, and LDH assays were performed to measure cytotoxicity. *, p ≤ 0.05 versus untreated (UT). B, NSG mice were subcutaneously injected with 2.5 × 106 MV4-11 cells and then treated with either PBS, anti-CD38 antibody, IFNγ, or a combination of anti-CD38 and IFNγ (n = 6/group). Tumor growth rate as well as final tumor volumes were measured. *, p ≤ 0.05 versus PBS control at day 17 for rate of tumor growth. Error bars, S.D.